Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Education | $1,439 | 1 | 51.2% |
| Food and Beverage | $1,369 | 125 | 48.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $1,439 | 1 | $0 (2022) |
| PFIZER INC. | $287.27 | 25 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $222.90 | 48 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $180.60 | 11 | $0 (2018) |
| Amgen Inc. | $100.74 | 6 | $0 (2018) |
| Novo Nordisk Inc | $95.50 | 5 | $0 (2020) |
| GlaxoSmithKline, LLC. | $90.78 | 6 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $84.43 | 6 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $73.74 | 3 | $0 (2018) |
| Lilly USA, LLC | $49.60 | 3 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $1,439 | 1 | Celgene Corporation ($1,439) |
| 2020 | $20.88 | 1 | Novo Nordisk Inc ($20.88) |
| 2018 | $445.28 | 32 | PFIZER INC. ($166.39) |
| 2017 | $902.38 | 92 | Merck Sharp & Dohme Corporation ($183.36) |
All Payment Transactions
126 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2022 | Celgene Corporation | — | Education | Cash or cash equivalent | $1,438.67 | General |
| 08/26/2020 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: Diabetes | ||||||
| 10/31/2018 | GlaxoSmithKline, LLC. | BREO (Drug) | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: RESPIRATORY | ||||||
| 10/27/2018 | PFIZER INC. | CHANTIX (Drug), ELIQUIS | Food and Beverage | In-kind items and services | $11.02 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 10/18/2018 | AstraZeneca Pharmaceuticals LP | SYMBICORT (Drug) | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: Respiratory | ||||||
| 10/10/2018 | PFIZER INC. | CHANTIX (Drug), LYRICA, COLOGUARD | Food and Beverage | In-kind items and services | $12.13 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 10/08/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $34.94 | General |
| 09/05/2018 | PFIZER INC. | CHANTIX (Drug), LYRICA | Food and Beverage | In-kind items and services | $14.02 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 08/02/2018 | PFIZER INC. | CHANTIX (Drug), ELIQUIS | Food and Beverage | In-kind items and services | $11.06 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 07/24/2018 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $13.73 | General |
| Category: RESPIRATORY | ||||||
| 07/24/2018 | Kowa Pharmaceuticals America, Inc. | Livalo (Drug), Vascepa | Food and Beverage | Cash or cash equivalent | $13.52 | General |
| Category: Cardiovascular | ||||||
| 07/12/2018 | PFIZER INC. | CHANTIX (Drug), LYRICA | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 06/26/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: DIABETES | ||||||
| 06/26/2018 | GlaxoSmithKline, LLC. | BREO (Drug), ADVAIR | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: RESPIRATORY | ||||||
| 06/18/2018 | PFIZER INC. | CHANTIX (Drug), ELIQUIS | Food and Beverage | In-kind items and services | $11.32 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 06/06/2018 | PFIZER INC. | CHANTIX (Drug), ELIQUIS | Food and Beverage | In-kind items and services | $11.73 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 05/26/2018 | PFIZER INC. | CHANTIX (Drug), LYRICA, EUCRISA | Food and Beverage | In-kind items and services | $2.04 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 05/23/2018 | Merck Sharp & Dohme Corporation | PNEUMOVAX 23 (Biological), GARDASIL9 | Food and Beverage | In-kind items and services | $13.41 | General |
| Category: VACCINE | ||||||
| 05/16/2018 | PFIZER INC. | CHANTIX (Drug), LYRICA | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 04/28/2018 | PFIZER INC. | CHANTIX (Drug), LYRICA, EUCRISA | Food and Beverage | In-kind items and services | $9.19 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 04/12/2018 | AstraZeneca Pharmaceuticals LP | SYMBICORT (Drug) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: Respiratory | ||||||
| 04/12/2018 | PFIZER INC. | CHANTIX (Drug), ELIQUIS | Food and Beverage | In-kind items and services | $10.12 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 03/28/2018 | Merck Sharp & Dohme Corporation | ZOSTAVAX (Biological), PNEUMOVAX 23, GARDASIL9 | Food and Beverage | In-kind items and services | $13.44 | General |
| Category: VACCINE | ||||||
| 03/21/2018 | PFIZER INC. | CHANTIX (Drug), LYRICA | Food and Beverage | In-kind items and services | $11.73 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 03/14/2018 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug), XARELTO | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: Cardiovascular & Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 273 | 423 | $85,461 | $17,766 |
| 2022 | 5 | 182 | 374 | $84,315 | $15,721 |
| 2021 | 7 | 239 | 431 | $84,016 | $28,946 |
| 2020 | 7 | 314 | 524 | $92,111 | $27,404 |
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 133 | 275 | $69,844 | $13,932 | 19.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 38 | 44 | $7,147 | $1,782 | 24.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 16 | 16 | $4,845 | $838.24 | 17.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 25 | 26 | $1,546 | $815.62 | 52.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 25 | 25 | $1,305 | $258.72 | 19.8% |
| G0403 | Electrocardiogram, routine ecg with 12 leads; performed as a screening for the initial preventive physical examination with interpretation and report | Office | 2023 | 16 | 16 | $763.00 | $129.02 | 16.9% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 20 | 21 | $10.50 | $10.29 | 98.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 115 | 295 | $74,340 | $13,644 | 18.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 18 | 27 | $4,347 | $1,183 | 27.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 12 | 12 | $3,408 | $591.22 | 17.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 23 | 26 | $1,534 | $155.06 | 10.1% |
| G0403 | Electrocardiogram, routine ecg with 12 leads; performed as a screening for the initial preventive physical examination with interpretation and report | Office | 2022 | 14 | 14 | $686.00 | $148.25 | 21.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 111 | 297 | $74,844 | $25,914 | 34.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 27 | 33 | $5,313 | $2,070 | 39.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 21 | 21 | $1,113 | $372.33 | 33.5% |
| G0009 | Administration of pneumococcal vaccine | Office | 2021 | 17 | 17 | $901.00 | $301.01 | 33.4% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 31 | 31 | $1,829 | $273.24 | 14.9% |
| 90732 | Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older | Office | 2021 | 17 | 17 | $8.50 | $8.50 | 100.0% |
| 90662 | Vaccine for influenza for injection into muscle, split virus, preservation free | Office | 2021 | 15 | 15 | $7.50 | $7.50 | 100.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 117 | 295 | $71,748 | $20,575 | 28.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 46 | 67 | $10,379 | $2,882 | 27.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 36 | 37 | $4,129 | $1,817 | 44.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 12 | 13 | $1,663 | $960.58 | 57.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 38 | 42 | $2,226 | $738.71 | 33.2% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2020 | 32 | 33 | $1,947 | $412.02 | 21.2% |
About Dr. David Kerzer, DO
Dr. David Kerzer, DO is a Family Medicine healthcare provider based in Cranston, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/04/2005. The National Provider Identifier (NPI) number assigned to this provider is 1487641411.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Kerzer, DO has received a total of $2,807 in payments from pharmaceutical and medical device companies, with $1,439 received in 2022. These payments were reported across 126 transactions from 19 companies. The most common payment nature is "Education" ($1,439).
As a Medicare-enrolled provider, Kerzer has provided services to 1,008 Medicare beneficiaries, totaling 1,752 services with total Medicare billing of $89,838. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Cranston, RI
- Active Since 10/04/2005
- Last Updated 10/01/2018
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1487641411
Products in Payments
- CHANTIX (Drug) $209.26
- INVOKANA (Drug) $91.75
- XARELTO (Drug) $88.85
- BELSOMRA (Drug) $74.75
- Victoza (Drug) $74.62
- Prolia (Biological) $74.22
- ZOSTAVAX (Biological) $72.39
- SYMBICORT (Drug) $72.12
- VIAGRA (Drug) $66.12
- TRULICITY (Drug) $49.60
- BREO (Drug) $48.80
- JANUVIA (Drug) $41.89
- PRALUENT ALIROCUMAB INJECTION (Biological) $30.40
- TRELEGY ELLIPTA (Drug) $27.30
- Repatha (Biological) $26.52
- PRALUENT (Drug) $24.42
- JARDIANCE (Drug) $21.70
- Myrbetriq (Drug) $20.96
- Ozempic (Drug) $20.88
- SOLIQUA (Drug) $20.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Cranston
Sukanya Somasundar, M.d, M.D
Family Medicine — Payments: $16,471
Dr. Michael Hayden, D.o, D.O
Family Medicine — Payments: $10,239
Dr. Matthew Salisbury, M.d, M.D
Family Medicine — Payments: $4,672
Miss. Madiha Ali, M.d, M.D
Family Medicine — Payments: $3,138
Dr. Michael Mccarten, D.o, D.O
Family Medicine — Payments: $1,297
Rachel Putrus, Md, MD
Family Medicine — Payments: $563.05